Becker muscular dystrophy is an X-linked disease due to mutations of the dystrophin gene. We now show that neuronal-type nitric oxide synthase (nNOS), an identified enzyme in the dystrophin complex, is uniquely absent from skeletal muscle plasma membrane in many human Becker patients and in mouse models of dystrophinopathy. An NH2-terminal domain of nNOS directly interacts with cxl-syntrophin but not with other proteins in the dystrophin complex analyzed. However, nNOS does not associate with cll-syntrophin on the sarcolemma in transgenic mdx mice expressing truncated dystrophin proteins. This suggests a ternary interaction of nNOS, ~l-syntrophin, and the central domain of dystrophin in vivo, a conclusion supported by developmental studies in muscle. These data indicate that proper assembly of the dystrophin complex is dependent upon the structure of the central rodlike domain and have implications for the design ofdystrophin-containing vectors for gene therapy.
M
utations of the X-linked dystrophin gene are the most common cause of inherited muscular dystrophy and affect ~1:3,500 male births (1) . Duchenne muscular dystrophy (DMD) I, the more common and more severe form of the disease, is associated with mutations that lead to an absence of dystrophin protein in muscle (2, 3) . A clinically milder disease, Becket muscular dystrophy (BMD), accounts for ~20% of cases and often involves deletions within the rodlike central domain of dystrophin (4) . Muscle dystrophin levels are often nearly normal in BMD, which can preclude diagnosis by immunohistochemical analysis ofdystrophin (5) .
Dystrophin is a large intracellular protein containing several defined sequence motis (6) . An NH2-terrninal cx-actinin-like domain binds to F-actin (7), and is followed by a large rod domain that shares sequence homology with the structural repeats in spectrin. The COOH terminus is unique to dystrophin and related proteins, and this region ~ Abbreviations used in this paper: oe-BGT, alpha bungaro-toxin; AChR, acetylcholine receptor; BMD, Becket muscular dystrophy; DMD, Duchenne muscular dystrophy; GST, glutathione-S-transferase; nNOS, neural-type nitric oxide synthase; NO, nitric oxide; PH, pleckstrim homology. direcdy binds to a glycoprotein complex in skeletal muscle (8) (9) (10) . The structural dystrophin-associated complex includes intracellular proteins, syntrophins (11) , as well as integral membranes proteins, the dystroglycans (12) and sarcoglycans; the absence of dystrophin in DMD causes a disruption of this complex (13) . These interactions suggest a structural role for dystrophin, physically linking the extracellular matrix to the muscle cytoskeleton (14) . In support of this model, genetic mutations in components of the sarcoglycan complex can cause autosomal recessive muscular dystrophy (15) (16) (17) (18) .
Restoration of a functional dystrophin molecule to muscle represents a primary goal for therapy. To better understand mechanisms for assembly of the dystrophin complex and to identify potential constructs for gene therapy, fragments of dystrophin have been targeted to skeletal muscle of transgenic mdx mice, which lack endogenous dystrophin. Replacement with either a full-length dystrophin, a COOH-terminal construct encoding 71 kD of dystrophin, Dp71, or a dystrophin minigene, lacking a large portion of the central spectrinlike repeats, restores the structural dystrophin complex to muscle. P..eplacement with full-length dystrophin corrects muscular dystrophy in mdx mice (19) . Despite apparent restoration of the dystrophin complex, mdx mice targeted with Dp71, still display severe muscular dystrophy (8, 9) , whereas those containing the minigene, have a very. mild disease phenotype (20, 21) . These results indicate that all components of the dystrophin membrane cytoskeleton are needed to completely prevent symptoms of muscular dystrophy.
In addition to their cytoskeletal role, dystrophin and associated proteins have been implicated in specific signaling functions of the junctional and extrajunctional sarcolemma. The dystrophin-related protein, utrophin, is concentrated at neuromuscular endplates and is implicated in acetylcholine receptor (AChl<) clustering, ot-dystroglycan binds with high affinity to agrin and laminin suggesting that the dystrophin-associated complex may serve as a link between the extracellular matrix and intracellular events that help form AChR. clusters (22, 23) . Signaling by the dystrophin complex may be mediated in part by nitric oxide (NO), a messenger molecule in muscle that can regulate myocyte development (24) , AChR. function (25) , and muscle contractility (26) . NO is formed in skeletal muscle by the neuronal-type nitric oxide synthase (nNOS) that is enriched at the sarcolemma of fast twitch muscle fibers in rodents (26) and in both fast and slow twitch fibers in primates (27) . R.ecent studies identify nNOS as a nonstructural component of the dystrophin complex (28) . Furthermore, nNOS is absent from skeletal muscle sarcolemma of mdx mice and in DMD (28) . Biochemical studies in vitro demonstrate that the NH 2 terminus of nNOS, which contains a PDZ protein motif, directly binds to a similar motif in cel-syntrophin (29) ; furthermore, nNOS and od-syntrophin coimmunoprecipitate from muscle extracts. Direct binding of nNOS to dystrophin or other associated proteins has not yet been demonstrated. DMD and mdx mice show primary dystrophin deficiency and secondary deficiencies of sarcoglycans, dystroglycans, syntrophins, and nNOS. BMD in humans, due to abnormal dystrophin, generally retains dystrophin-associated proteins, though nNOS has not been evaluated. We now show that nNOS is properly restored to the plasma membrane in transgenic mdx mice expressing full-length human dystrophin but is selectively absent from skeletal muscle membranes in mdx mice expressing either Dp 71 (DMD phenotype) or a dystrophin minigene lacking many of the spectrinlike repeats (very mild BMD phenotype). Dyslocalization of nNOS in the transgenic mouse nmdels is associated with disruption of the normal nNOSAxl-syntrophin interaction. In human biopsies, we note that loss of sarcolemmal nNOS is commonly observed in BMD. In some patients, lacking as little as three exons in the spectrinlike domain of dystrophin, the absence of sarcolemmal nNOS represents the only identified immunohistochemical abnormality.
Materials and Methods
Antibodies. The following primary antibodies were used: nNOS polyclonal raised against homogenous nNOS protein purified from rat cerebellum (30) , nNOS monoclonai (Transduction Labs, Lexington, KY), od-syntrophin polyclonal, syntrophin monoclonal (31), dystrophin monoclonal (Signna Chemical Co., St. Louis, MO), [3-dystroglycan monoclonal, utrophin monoclonal, and a-sarcoglycan rnonoclonal (Novacastra Laboratories Ltd., Newcastle upon Tyne, UK).
lmmunofluorescence. Unfixed skeletal muscle samples were flash frozen in liquid nitrogen-cooled isopentane, sectioned on a cryostat (10 Ixm), and melted directly onto glass slides. Sections were then postfixed in 2% paraformaldehyde in PBS or cold acetone. Tissues were "blocked" in PBS containing 1% normal goat sermn. Primary antibodies were diluted in blocking reagent and were applied to sections overnight at 4~ For indirect immunofluorescence, secondary goat anti-rabbit FITC-, or donkey antimouse Cy-3-conjugated antibodies were used according to the manufacturer's specifications (The Jackson Laboratory, Bar Harbor, ME; 1:200)_ Cy-3-conjugated 0~-BGT (kindly provided by Peter Sargent, University of California, San Francisco) was diluted together with the secondary antibody t-or double labeling motor endplates.
Tissue Extraction1 and Western Blot Analysis. Mouse quadriceps skeletal nmscle was homogenized in 1(1 volumes (wt/vol) of buffer A (25 mM Tris-HC1, pH 7.4, 100 mM NaCl, 1 mM EDTA, l mM EGTA, and 1 mM PMSF), and heavy, microsomes were prepared by a standard protocol with minor modifications. Nuclei were pelleted by centrifugation at 1,000 ,~. The supernatant was then centrifuged at 20,000 ,~, yielding supernatant S~. The resulting heavy microsomal pellet was resuspended in buffer A containing 500 mM NaC1, incubated for 30 rain at 4~ with agitation, and centrifuged at 15,000 ,~, yielding supernatant S,. This resulting pellet was resuspended in buffer A containing 5~0 mM NaC1 plus 0.5% Triton X-100, incubated for 30 mm at 4o( ", with agitation, and centrifuged at 15,000 ,~, yielding supernatant $3 and a final pellet P.
Tissue extracts were resolved by SDS-PAGE (7.5% acrylamide) and proteins were transferred to polyvinylidene fluoride membranes (hnmobilon-P; Millipore Corp., Bedford, MA). Membranes were incubated overnight with primary antisera diluted in Tris-HC1 buffered saline containing 1% BSA, hnnmnoreactive bands were visualized by the enhanced chemiluminescence system according to the manufacturer's specifications (Amersham Corp., Arlington Heights, ILl.
Immunoprecipitation. Polyctonal antibodies (1 ~g) to od-syntrophin or noninmmne serum were added to 0.5-ml aliquots of solubilized skeletal muscle membranes from wild-type mouse (1 mg/ml) or total solubilized nmscle extract from mdx mouse (2 mg/ml), and samples were incubated on ice fbr 1 h. Protein A-Sepharose (50 p,1) was used to precipitate antibodies. Protein A pellets were washed three times with buffer containing I{t0 mM NaCI and 1% Triton X-100. Immunoprecipitated proteins were denatured with loading buffer and resolved by SDS-PAGE.
Fusion P~vtein Aflb~ity Chromatq~raphl,. A thsion protein of glutathione-S-transferase (GST) fused to the first 299 amino acids of nNOS was expressed in Escheridzia coil and purified on glutathione Sepharose beads as described (28) . Solubilized skeletal muscle membranes were incubated with control ((;ST) or GSTnNOS (1-299) beads. Samples were loaded into disposable colunms washed with 5(1 volumes of buffer containing 0.5% Triton X-I(10 plus 3(}(I mM NaC1, and proteins were eluted with 150 p,1 of SDS-PAGE loading buffer.
Characterization qfHumal~ Tissues. All human muscle biopsies were obtained for diagnostic purposes (dystrophin analysis), and were flash frozen in isopentane cooled in liquid nitrogen. Patients were evaluated for dystrophin expression by immunofluorescence and Western blotting as described (32, 33) . Mutation detection in BMD patients was done by multiplex PCR, as previously described. Mutation detection in or (adhalin) was done by R T -P C R and single strand conformation polymorphism, with aberrant conformers sequenced as previously described (34); one patient was homozygous for an Arg77Cys mutation whereas another was a compound heterozygote, Leu31Pro and Arg284Cys. All biopsies used in this study were deemed to be of excellent preservation based on hematoxylin and eosin staining of cryosections.
Results
Previous studies suggest that association of n N O S with the dystrophin complex is mediated by direct binding o f the NH2-terminus of n N O S to the P D Z domain o f c~l-syntrophin (29) . However, during skeletal muscle development, we found a dissociation between n N O S and oel-syntrophin localization in muscle. Throughout postnatal rat development, otl-syntrophin was present at extrajunctional sarcolemma and was particularly enriched at neuromuscular endplates (Fig. 1) . By contrast, at postnatal day 3 (P3) and P7, n N O S was observed only at extrajunctional sarcolemma. Enrichment o f n N O S at neuromuscular endplates did not become apparent until P12, coincident with accumulation o f dystrophin at endplates. Utrophin was enriched at endplates in all stages evaluated.
W e compared n N O S and otl-syntrophin expression in Figure 1 . Localization of nNOS and other dystrophin-associated proteins during postnatal development. Adjacent sections of postnatal rat quadriceps muscle were stained for dystrophin, nNOS, oe-BGT, and utrophin, and nearby sections were stained for otl-syntrophin and cx-BGT. Dystrophin and uNOS stained extrajunctional sarcolemma at P3 and P7 and both became concentrated at neuromuscular endplates at P12 and P60. otl-syntrophin was present at extrajunctional sarcolemma and was enriched at neuromuscular endplates at all ages evaluated. Utrophin staining was restricted to neuromuscular endplates. Figure 2 . Localization of nNOS and ~xl-syntrophin in transgenic mdx mice. Cryosections from mouse quadriceps were double labeled for either nNOS or ~xl-syntrophin and cr Immunofluorescent staining showed that nNOS in wild-type mouse was expressed at extrajunctional sareolemma of a subset of fibers and was enriched at all neuromuscular endplates, nNOS was absent from junctional and extrajunctional sarcolemma in mdx mice. nNOS staining in mdx transgenic mice expressing full-length dystrophin (full-dys) or truncated dystrophin lacking the COOH-termina1330 nucleotides (A331)) resembled that of wild-type mice. mdx mice expressing dystrophin-lacking exons 17--48 (AEXON 17-48 mini-dys) or the COOH-terrmna171 kD of dystrophin Dp7l lacked nNOS staining at sarcolemma, similar to nontransgenic mdx mouse, otl-syntrophin occurred at extrajunctional sarcolemma a~ad was concentrated at neuromuscular endplates in wild-type mice and was restricted to the endplates in mdx mouse, cd-syntrophin expression was restored to sarcolemma in the four transgenic mdx mouse lines expressing different portions of the dystrophin gene.
skeletal muscle of wild-type, mdx, and various transgenic mdx mice (Fig. 2) that express mutant forms of dystrophin (8, 9, (19) (20) (21) 35) . As previously reported, otl-syntrophin was absent from extrajunctional sarcolemma of mdx mouse, b u t remained at neuromuscular endplates (31, 36) . n N O S was absent from both junctional and extrajunctional sarcolemma of mdx mouse. Four lines of mdx transgenic mice were evaluated. These previously described lines express ei- Mouse quadriceps skeletal muscle homogenates were sequentially extracted with buffers containing 100 mM NaC1 (S1), 500 mM NaCI ($2), and 0.5% Triton X-100 ($3), leaving an insoluble cytoskeletal pellet (P). (A) Western blotting indicated that nNOS was enriched in membraneassociated and pellet fractions in wild-type mouse (lanes 1) and transgenic mdx mice expressing full-length dystrophin (lanes 4). In mdx mouse (lanes 2) and Dp71 transgenic mdx mouse (lanes 3), nNOS was fully extracted by 500 mM NaCI and was absent from membrane-associated and cytoskeletal fractions. (B and C) A similar fractionation was performed on muscle homogenates from wild-type nmuse (lanes 1), mdx mouse expressing dystrophin-lacking exons 17-48 (lanes 2), or mdx mouse expressing fill-length dystrophin (lanes 3). (B) nNOS was absent from membraneassociated ($3) and cytoskeletal pellet (P) in mdx mouse expressing the truncated dystrophin. (C) R.eprobing the blot shows that od-syntrophin had a generally similar fractionation in nmscle from all three mice lines. p o r t e d , o L l -s y n t r o p h i n e x p r e s s i o n was r e s t o r e d to j u n ctional a n d e x t r a j u n c t i o n a l s a r c o l e m m a in e a c h o f t h e f o u r transgenics. B y contrast, n N O S was r e s t o r e d to t h e s a r c ol e m m a o n l y b y f u l l -l e n g t h d y s t r o p h i n a n d t h e A 3 3 0 m utant. Figure 4 . Selective interaction ofnNOS and od-syntrophin. Crude solubilized membranes from mouse quadriceps were titrated with NaOH to pH 11, to dissociate the dystrophin complex, and were neutralized to pH 7.4 with 1 M Tris-HC1. Native and dissociated (&~soc) preparations were incubated with agarose beads linked to either GST or GST fused to the first 299 anfino acids ofnNOS (G-NOS). After extensive washing, beads were eluted with loading buffer and proteins were resolved by SDS/PAGE. (A) Westem blotting showed that txl-syntrophin was selectively retained by G-NOS beads in both native and dissociated preparations. Reprobing the same blot with (B) dystrophin or (C) ot-sarcoglycan revealed that G-NOS beads retained these proteins from native protein preparations. However, after dissociation of the complex, neither dystrophin nor ot-sarcoglycan bound to G-NOS. The 55-kD band observed in input lanes from r blot appears to be mouse IgG and was reactive with the secondary antibody used for Western blotting. (D) Coimmunoprecipitation ofnNOS with otl-syntrophin from wild-type and mdx mouse skeletal muscle. Total solubilized extract from mdx (lanes 1 and 2) or solubilized membranes from wild-type (lanes 3 and 4) mouse quadriceps were immunoprecipitated with an antibody to od-syntrophin (lanes 1 and 3) or nonimmune serum (lanes 2 and 4). Western blotting indicates that nNOS was specifically coimmunoprecipitated with oel-syntrophin from mdx and wild-type extracts. 3 , and data not shown). Whereas these studies are consistent with the model that association of nNOS with ed-syntrophin in vivo requires a full-length dystrophin, direct binding ofnNOS to the rodlike domain of dystrophin or another dystrophin-associated protein could also explain the data. Previous studies demonstrate that the NH2-terminal domain ofnNOS is necessary and sufficient for interaction with the dystrophin complex (28) . We therefore evaluated interaction of dystrophinassociated proteins with a purified fusion protein containing the first 299 amino acids ofnNOS. As previously demonstrated, a Sepharose column linked to this fusion protein selectively retained several components of the dystrophin complex from crude skeletal muscle extracts. To determine which components directly interact with nNOS in vitro, we dissociated the dystrophin complex by briefly adjusting the pH of muscle extracts to 11 and then repeating the binding assays immediately after neutralizing the extracts. Previous studies (37) have demonstrated that this procedure reversibly dissociates dystrophin from associated proteins. After dissociation of the complex, ed-syntrophin continued to interact with the nNOS column but dystrophin, tx-sarcoglycan, and [3-dystroglycan were not retained (Fig. 
4, A-C and data not shown).
To further verify that nNOS directly interacts with syntrophin in vivo, we conducted inmmnoprecipitation experiments in mdx mouse (Fig. 4/7) ). A polyclonal antibody to ed-syntrophin specifically coimnmnoprecipitated a small amount of nNOS from extracts of mdx skeletal nmscle.
nNOS was more efficiently coinmmnoprecipitated with e~ 1-syntrophin from solubilized membranes of wild-type mouse as previously shown (29) .
We next asked whether mutations in the NH2-terminal or rodlike domains of dystrophin that cause BMD in humans were associated with altered localization of nNOS. We immunohistochemically evaluated nNOS and txl-syntrophin expression in 12 BMD patients with molecularly defined deletions in the dystrophin gene. Immunohistochemical expression of nNOS, dystrophin, and syntrophin were assessed blindly. Loss ofsarcolemmal nNOS, but not cd-syntrophin expression was associated with Becker phenotype (Table 1) . Some of the patients, with mild to intermediate disease, showed reduced but detectable nNOS Figure 5 . nNOS is absent from skeletal muscle sarcolemma in certain patients with BMD. Skeletal muscle cryosections from human biopsies were immunostained with monoclonal antibodies to dystrophin, syntrophin, ot-sarcoglycan, or polyclonal antibody nNOS. All four antibodies showed sarcolemmal staining in normal patients and essentially no sarcolemmal labeling in patients with DMD. In two patients with BMD, due to loss of exons 45-47 or 10-42 of dystrophin, immunofluorescent labeling for dystrophin, syntrophin, and ot-sarcoglycan was detected at the membrane. By contrast, nNOS sarcolemmal staining was undetectable in these two BMD patients, nNOS labeling was present in a patient with ot-sarcoglycan deficiency. staining ofsarcolemma. In several patients, loss ofsarcolemmal n N O S occurred despite apparently normal assembly of other components o f the dystrophin-associated glycoprotein complex (Fig. 5) . By contrast, we found that n N O S expression was intact in two patients with primary et-sarcoglycan deficiency. This is consistent with the normal status of dystrophin and syntrophins in this disorder.
Discussion
A principal finding of this work is that assembly of n N O S into the dystrophin complex is dependent upon the normal structure o f the rodlike domains ofdystrophin. Previous analyses of specific protein contacts involved in maintenance o f the dystrophin complex have focused on protein interactions at the N H 2-and C O O H -t e m n i n a l domains of dystrophin. These studies identify a functional F-actin binding site near the N H a -t e r m i n u s (7) and binding sites for 13-dystroglycan and syntrophins in the C O O H -t e r m inal domain of dystrophin (10) . Understanding the mechanism for n N O S association with the dystrophin complex is important because n N O S is uniquely absent from sarcolemma in certain animal models of muscular dystrophy and in certain patients with BMD. Absence o f sarcolemmal n N O S in mdx mouse expressing a dystrophin minigene indicates a role for the rodlike domain of dystrophin for binding of n N O S . Studies of n N O S expression in B M D patients demonstrate that distinct deletions in the NH2-terminal or central domain of dystrophin disrupt recruitment o f n N O S to the sarcolemma. These results indicate that a unique nNOS interaction domain may not be present in dystrophin, but that proper conformation is required for assembly ofnNOS into the dystrophin complex.
Previous studies suggest that direct interaction of nNOS with 0d-syntrophin accounts for association of nNOS with the dystrophin complex (29) . Three syntrophin genes have been identified and each contains two pleckstrin homology (PH) domains. The first PH domain is split by a PDZ motif, and the second PH domain is followed by a COOHterminal region unique to the syntrophins (38) . Interaction of nNOS with ~xl-syntrophin is mediated by direct association of PDZ protein-binding interfaces near the NH2-terminus of nNOS and cxl-syntrophin. Studies here are consistent with this model and demonstrate that &l-syntrophin, but not dystrophin, [3-dystroglycan or cl-sarcoglycan binds to the PDZ-containing domain of nNOS. NOS isoforms lacking a PDZ motif do not associate with the dystrophin complex, further suggesting that the PDZ domain of nNOS represents the relevant domain for interaction (29) .
The precise binding site(s) for syntrophins within the dystrophin complex is uncertain. In vitro studies show that the COOH-terminal region of syntrophin directly interacts with a splice-prone COOH-terminal domain ofdystrophin (39) (40) (41) . However, syntrophins are present in dystrophin complexes of the A330 transgenic mouse that lacks the identified syntrophin interaction domain, suggesting additional bindings sites for syntrophins (35) . It is not clear which domain of syntrophins might interact with these additional sarcolemmal binding sites. PH domains are known to interact with specific membrane proteins and phospholipids (42) , and these regions of syntrophins represent candidate interaction domains. Because the first PH domain of syntrophin is split by the PDZ domain (38) , it is possible that sinmltaneous occupation of the PH1 and PDZ sites is sterically prohibited. Therefore, membrane association of syntrophin mediated by its PH domains could preclude binding of nNOS to the PDZ domain. This may explain the observed sarcolemmal expression of syntrophin and absence ofnNOS in certain disease states.
nNOS appears not to interact with utrophin-containing complexes. During early postnatal muscle development, nNOS is not concentrated with complexes of cxl-syntrophin and utrophin at neuromuscular endplates. Similarly, utrophin complexes at neuronmscular endplates of mdx mouse lack nNOS. Taken together with biochemical studies showing direct interaction of nNOS with Rl-syntrophin in vitro, we propose that sarcolemmal localization of nNOS requires both syntrophin and dystrophin. It is alternatively possible that nNOS primarily binds directly to dystrophin in vivo. We have, however, been unable to detect direct interaction between nNOS and dystrophin in vitro and would disfavor this model. Future studies ofnNOS expression in mice lacking syntrophin isoforms may be necessary to definitively clarify this issue.
Loss of sarcolemmal nNOS does not appear to be a generic consequence of muscle disease, nNOS expression occurs normally at the sarcolemma in a variety of inflammatory, neuropathic, and idiopathic muscle disorders (Chao, D.S., and D.S. Bredt, unpublished observations), and in dy mutant mice that have muscular dystrophy associated with loss of extracellular M-laminin (merosin; 28). Three patients with similar deletions of exons 45-47 of dystrophin all showed loss of sarcolemmal nNOS but exhibited a wide spectrum of clinical variability. This domain of dystrophin is apparently critical for assembly ofnNOS, and the clinical differences could be caused by environmental and/or epigenetic factors, nNOS was expressed normally in two patients with autosomal recessive muscular dystrophy due to mutations in oL-sarcoglycan (adhalin). Abnormality of nNOS expression, therefore, appears specific for dystrophin-related disease, and immunohistochernical analysis for nNOS may provide a supplemental diagnostic test.
Abnormal expression of nNOS may play a role in the pathophysiology of BMD. Decreased expression of nNOS alone is not sufficient to produce muscular dystrophy, as we have not detected muscle pathology in nNOS a/a mice that have a targeted disruption ofnNOS (Chao, D.S., and D.S. Bredt, unpublished observations). However, endogenous NO does play a role in regulation of skeletal muscle development and contractility (24, 26) . Disruption of these NO signaling pathways may contribute to abnormal nmscle function and incomplete myofiber regeneration seen in muscular dystrophy. In mdx mice expressing Dp71 or dystrophin minigene, nNOS is the only known dystrophinassociated protein absent from the sarcolemnaa. Transgenic mdx mice expressing the dystrophin minigene have an extremely mild muscular dystrophy characterized by only a modest increase in central nuclei and serum pyruvate kinase activity (20, 21) . A human patient with an identical mutation had a mild dystrophy and was ambulatory with the aid of a stick at age 61 (43) . In contrast to the mild clinical phenotype, this minigene mutation in a 25-year-old patient was associated with severe histopathological nmscle fiber atrophy, extensive replacement by fat and fibrous connective tissue, and few surviving fibers of normal diameter (43) .
These findings may be relevant in designing therapies for DMD. We find that nNOS does not associate with utrophin-containing complexes, so that strategies for upregulation ofutrophin in DMD would not be expected to restore sarcolemmal nNOS. Because of the large size of the dystrophin protein, vectors for gene therapy may need to encode truncation mutants. Expression ofa minigene lacking exons 17-48 of dystrophin fails to recruit nNOS to sarcolemma of mdx mouse and is associated with a very mild Becket phenotype. Complete rescue of muscle function may require replacement with dystrophin constructs that properly recruit nNOS to skeletal muscle membranes.
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